Evidence map›Paper›PMID 36829732›Full record

ArticleBioengineering (Basel, Switzerland)2023

Evaluating Hydroxyapatite, Gold Nanoparticles, and Graphene-Copper as Bimodal Agents for X-ray and Computed Tomography.

Bruno Pugliese Pereira, Claudia Antoine, Aline Oliveira da Silva de Barros, Leonardo de Castro Pacífico, Martha Sahylí Ortega Pijeira, Alexandre Malta Rossi, Eduardo Ricci-Junior, Luciana Magalhães Rebelo Alencar, Ralph Santos-Oliveira

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Bruno Pugliese PereiraLaboratory of Nanoradiopharmacy and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute Brazilian Nuclear Energy Commission, Rio de Janeiro 21941906, RJ, Brazil.
Claudia AntoineLaboratory of Nanoradiopharmacy and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute Brazilian Nuclear Energy Commission, Rio de Janeiro 21941906, RJ, Brazil.
Aline Oliveira da Silva de BarrosLaboratory of Nanoradiopharmacy and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute Brazilian Nuclear Energy Commission, Rio de Janeiro 21941906, RJ, Brazil.
Leonardo de Castro PacíficoDepartment of Radiological Sciences, Institute of Biology Roberto Alcântara Gomes State University of Rio de Janeiro, Rio de Janeiro 20550013, RJ, Brazil.
Martha Sahylí Ortega PijeiraLaboratory of Nanoradiopharmacy and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute Brazilian Nuclear Energy Commission, Rio de Janeiro 21941906, RJ, Brazil.ORCID 0000-0001-9307-4954
Alexandre Malta RossiDepartment of Condensed Matter, Applied Physics and Nanoscience, Brazilian Center for Research in Physics, Rio de Janeiro 22290180, RJ, Brazil.
Eduardo Ricci-JuniorSchool of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21941900, RJ, Brazil.
Luciana Magalhães Rebelo AlencarBiophysics and Nanosystems Laboratory, Department of Physics, Federal University of Maranhão, São Luis 65065690, MA, Brazil.ORCID 0000-0001-8210-2016
Ralph Santos-OliveiraLaboratory of Nanoradiopharmacy and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute Brazilian Nuclear Energy Commission, Rio de Janeiro 21941906, RJ, Brazil.ORCID 0000-0002-0905-481X
Nuclear Engineering Institute · BRUniversidade do Estado do Rio de Janeiro · BRBrazilian Center for Research in Energy and Materials · BRUniversidade Federal do Maranhão · BRUniversidade Federal do Rio de Janeiro · BR

Funding

National Council for Scientific and Technological Development bolsa produtividade
6 · The paper itself

Abstract

A global need exists for new and more effective contrast agents for computed tomography and traditional X-ray modalities. Among the few options available nowadays, limitations imposed by industrial production, performance, and efficacy restrict the use and reduce the potential of both imaging techniques. The use of nanomaterials as new contrast agents for X-ray and computed tomography is an innovative and viable way to increase the options and enhance performance. In this study, we evaluated eight nanomaterials: hydroxyapatite doped with zinc (Zn-HA 10%); hydroxyapatite doped with strontium (Sr-HA 10%); hydroxyapatite without thermal treatment (HA 282 STT); thermally treated hydroxyapatite (HA 212 500 °C and HA 01.256 CTT 1000 °C); hydroxyapatite microspheres (HA microspheres); gold nanoparticles (AuNP); and graphene oxide doped with copper (Cu-GO). The results showed that for both imaging modalities; HA microspheres were the best option, followed by hydroxyapatite thermally treated at 1000 °C. The nanomaterials with the worst results were hydroxyapatite doped with zinc (Zn-HA 10%), and hydroxyapatite doped with strontium (Sr-HA 10%). Our data demonstrated the potential of using nanomaterials, especially HA microspheres, and hydroxyapatite with thermal treatment (HA 01.256 CTT 1000 °C) as contrast agents for X-ray and computed tomography.

Indexed as

biomedicaldiagnosismedicalnanotechnologyradiology

Identifiers

PMID36829732
PMCPMC9952155
OpenAlexW4320492403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.